More Information About - Oxima Acucap 150mcg - 150mcg
Description
Generic Name
Indacaterol
Precaution
Not intended for treatment of asthma and acute deterioration of COPD. Patient w/ acutely deteriorating COPD, thyrotoxicosis, seizure disorders, DM, hypokalaemia, CV disorders esp coronary insufficiency, cardiac arrhythmias or HTN. Pregnancy and lactation.
Lactation: Unknown whether distributed in human breast milk; use caution
Indication
Indacaterol Maleate is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with, chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Contra Indication
All LABA are contraindicated in patients with asthma without use of a long-term asthma control medication. Indacaterol is not indicated for the treatment of asthma. Indacaterol is contraindicated in patients with a history of hypersensitivity to indacaterol or to any of the ingredients.
Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks
Mode of Action
Indacaterol is a long acting ?2-adrenergic agonist. It relaxes the bronchial smooth muscle by selective action on ?2-receptor which acts locally in the lungs and w/ little effect on heart rate.
Interaction
Potentiated adverse effects w/ other sympathomimetic agents; possible hypokalaemic effect w/ methylxanthine derivatives, steroids or non-K-sparing diuretics. Other long-acting beta2-adrenergic agonists or medicinal products containing long-acting beta2-adrenergic agonists. Inhibition of the key contributors of indacaterol clearance, CYP3A4 and P-gp.
Pregnancy Category Note
Pregnancy Category: C
Beta-agonists are known to inhibit uterine contractility
Lactation: Unknown whether distributed in human breast milk; use caution
Adult Dose
Inhalation
Maintenance therapy in chronic obstructive pulmonary disease
Adult: As inhal cap: Inhale 75-150 mcg once daily using inhaler.
Max: 300 mcg once daily.
Hepatic impairment
No dose adjustment is required for patients with mild and moderate hepatic impairment.
There are no data available for use of Onbrez Breezhaler in patients with severe hepatic impairment.
Child Dose
Safety and efficacy not established
Renal Dose
Renal impairment
No dose adjustment is required for patients with renal impairment.
Administration
N/A
Disclaimer
The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.